atyr
pharma
announces
million
common
stock
purchase
agreement
aspire
capital
fund
llc
aspire
capital
commits
purchase
million
common
stock
period
months
san
diego
globe
newswire
atyr
pharma
nasdaq
life
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
immunological
pathways
today
announced
entered
common
stock
purchase
agreement
agreement
providing
sale
million
common
stock
aspire
capital
fund
llc
aspire
capital
institutional
investor
shareholder
atyr
terms
agreement
aspire
capital
committed
purchase
million
atyr
common
stock
period
months
prices
based
market
price
time
sale
subject
certain
terms
conditions
atyr
control
timing
amount
shares
common
stock
sold
aspire
capital
warrants
options
financing
swaps
derivatives
securities
associated
agreement
atyr
retains
right
terminate
agreement
time
discretion
without
additional
cost
penalty
excited
enter
agreement
aspire
capital
valued
shareholder
strong
supporter
scientific
platform
said
sanjay
shukla
president
chief
executive
officer
atyr
transaction
provides
opportunity
atyr
access
capital
efficient
flexible
manner
allowing
us
support
advancement
clinical
program
including
trials
pulmonary
sarcoidosis
severe
respiratory
complications
preclinical
programs
antibody
development
trna
synthetase
pleased
expand
investment
atyr
company
dedicated
developing
new
therapies
patients
diseases
high
unmet
medical
need
said
steven
martin
managing
member
aspire
capital
equity
vehicle
enhances
atyr
ability
leverage
broad
portfolio
intellectual
property
provides
aspire
capital
opportunity
invest
emerging
life
science
company
look
forward
developing
relationship
atyr
providing
ongoing
support
work
towards
achieving
several
notable
milestones
remainder
throughout
next
two
half
impressed
atyr
thoughtful
approach
drug
discovery
development
including
antibody
program
engineering
antibodies
said
michael
burrows
vice
president
life
sciences
aspire
capital
preclinical
data
generated
oncology
presented
american
association
cancer
research
annual
meeting
june
nice
first
step
demonstrating
initial
efficacy
blocking
showing
tumor
inhibitory
effects
look
forward
subsequent
data
limitations
use
proceeds
financial
business
covenants
restrictions
future
financings
additional
details
regarding
agreement
set
forth
atyr
current
report
form
filed
today
securities
exchange
commission
press
release
shall
constitute
offer
sell
solicitation
offer
buy
securities
shall
sales
securities
state
jurisdiction
offer
solicitation
sale
would
unlawful
prior
registration
qualification
securities
laws
state
jurisdiction
atyr
atyr
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
immunological
pathways
atyr
research
development
efforts
concentrated
newly
discovered
area
biology
extracellular
functionality
signaling
pathways
trna
synthetases
atyr
built
global
intellectual
property
estate
directed
potential
pipeline
protein
compositions
derived
trna
synthetase
genes
extracellular
targets
atyr
primary
focus
product
candidate
binds
receptor
designed
immune
engagement
inflammatory
lung
diseases
information
please
visit
http
aspire
capital
fund
llc
aspire
capital
fund
llc
investment
fund
focused
making
open
market
direct
equity
investments
publicly
traded
companies
aspire
capital
fund
llc
managed
aspire
capital
partners
llc
aspire
capital
invests
broad
range
industries
emphasis
healthcare
technology
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
usually
identified
use
words
anticipates
believes
estimates
expects
intends
may
plans
projects
seeks
variations
words
similar
expressions
intend
statements
covered
safe
harbor
provisions
statements
making
statement
purposes
complying
safe
harbor
provisions
statements
include
statements
regarding
potential
therapeutic
benefits
applications
antibody
program
timelines
plans
respect
certain
development
activities
including
development
antibody
program
potential
sales
common
stock
proceeds
agreement
certain
development
goals
statements
also
reflect
current
views
plans
intentions
expectations
strategies
prospects
based
information
currently
available
us
assumptions
made
although
believe
plans
intentions
expectations
strategies
prospects
reflected
suggested
statements
reasonable
give
assurance
plans
intentions
expectations
strategies
attained
achieved
statements
based
estimates
assumptions
management
although
believe
reasonable
inherently
uncertain
furthermore
actual
results
may
differ
materially
described
statements
affected
variety
risks
factors
beyond
control
including
without
limitation
fact
biology
fully
understood
uncertainty
regarding
pandemic
including
risk
delays
enrollment
clinical
trials
risks
associated
discovery
development
regulation
product
candidates
including
risk
results
clinical
trials
studies
may
support
development
risk
may
cease
delay
preclinical
clinical
development
activities
existing
future
product
candidates
variety
reasons
fact
collaboration
agreements
subject
early
termination
whether
able
satisfy
conditions
required
sell
shares
common
stock
aspire
capital
agreement
risk
may
able
raise
additional
funding
required
business
product
development
plans
well
risks
set
forth
recent
annual
report
form
quarterly
reports
form
sec
filings
except
required
law
assume
obligation
update
publicly
statements
whether
result
new
information
future
events
otherwise
